Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  11:59:58 2023-03-21 am EDT
1006.80 DKK   +1.81%
10:38aBlue shield of california - low-cost insulin one step closer with california-civica partnership
AQ
03/20Global markets live: UBS, Berkshire Hathaway, First Republic Bank, Goldman Sachs...
MS
03/20Novo Nordisk A/S - share repurchase programme
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk suspended from UK trade association for "serious breaches"

03/16/2023 | 05:06am EDT
FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen

LONDON (Reuters) - British pharma trade body, the Association of the British Pharmaceutical Industry (ABPI), on Thursday said it has suspended Danish drugmaker Novo Nordisk for two years due to "serious breaches."

ABPI's statement linked to a website of a self-regulatory body run by the association that pointed to complaints about Novo Nordisk-sponsored courses on weight management offered on LinkedIn.

Novo is the market leader in a rapidly growing area: the use of medicines - as opposed to dieting or exercising alone - to lose weight.

"While we are disappointed with this outcome, we accept the decision. We will remain committed to following the ABPI Code of Practice and maintaining the highest possible ethical standards required by the pharmaceutical industry," a company spokesperson said.

(Reporting by Natalie Grover in London and Ludwig Burger in Frankfurt; Editing by Toby Chopra)


ę Reuters 2023
All news about NOVO NORDISK A/S
10:38aBlue shield of california - low-cost insulin one step closer with california-civica par..
AQ
03/20Global markets live: UBS, Berkshire Hathaway, First Republic Bank, G..
MS
03/20Novo Nordisk A/S - share repurchase programme
GL
03/20Novo Nordisk Replenishes Supplies of Diabetes Drug Ozempic After Shortages
MT
03/17Financial Stocks Burden European Equities Again Friday Trading
MT
03/16France's Sanofi Joins Rivals in Slashing US Insulin Prices
MT
03/16Sanofi cuts insulin cost to $35, third major drug company to do so
AQ
03/16Sanofi to cut US price of its most-prescribed insulin by 78%
RE
03/16Sanofi to cut price of its most-prescribed insulin by 78% in US
RE
03/16European Central Bank's As-Expected Rate Hike Helps Stabilize Stocks
MT
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2023 208 B 30 160 M 30 160 M
Net income 2023 71 491 M 10 348 M 10 348 M
Net cash 2023 7 742 M 1 121 M 1 121 M
P/E ratio 2023 31,4x
Yield 2023 1,52%
Capitalization 2 265 B 328 B 328 B
EV / Sales 2023 10,8x
EV / Sales 2024 9,50x
Nbr of Employees 54 789
Free-Float 75,0%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 006,80 DKK
Average target price 1 016,23 DKK
Spread / Average Target 0,94%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S5.43%320 277
JOHNSON & JOHNSON-12.88%402 206
ELI LILLY AND COMPANY-8.81%300 873
ABBVIE INC.-3.40%275 418
MERCK & CO., INC.-4.60%268 710
PFIZER, INC.-20.36%230 348